Azole-resistant Aspergillus fumigatus (ARAF) has been reported in patients with chronic obstructive pulmonary disease (COPD) but has not been specifically assessed so far.
| INTRODUCTION
Patients with chronic obstructive pulmonary disease (COPD) are at risk for Aspergillus colonization 1,2 and invasive aspergillosis (IA), which has a 1.6%-3.9% prevalence, 3, 4 and is associated with high mortality.
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Azole-resistant Aspergillus fumigatus (ARAF) has been reported in the UK in four itraconazole-treated COPD patients (3 with chronic pulmonary aspergillosis and one with IA 6 ), in one patient with IA who had received voriconazole for 2 days in Denmark, 7 and in two azolenaïve patients colonized with TR 46 /Y121F/T289A A. fumigatus in the Netherlands. 8 However, although the emergence of ARAF is increasingly studied in hematology IA (1%-15.9% prevalence [9] [10] [11] ), cystic fibrosis (4.5%-8% prevalence [11] [12] [13] ), or intensive care units (ICU) patients (4.5%-26% prevalence 10, 14 ), the epidemiology and potential clinical impact of A. fumigatus azole resistance in patients with COPD have not been specifically assessed so far.
Furthermore, the presence of ARAF isolates has also been increasingly reported in the environment in several European countries, in
Asia and in South America, supporting the role of azole fungicides used in agriculture in the emergence of drug resistance. [15] [16] [17] As most patients acquire A. fumigatus from the environment, the emergence and spread of azole-resistant strains in the environment will put more humans at risk. However, only a few studies have combined environmental assessment and clinical data, two of them reporting ARAF isolates (TR 34 /L98H or TR 46 /Y121F/T289A) in the soil around the home of hematology patients with IA due to isolates carrying the same mutation. 18, 19 Interestingly, in one of these two studies, ARAF isolates were further found in the patient's home. 19 Another study compared the prevalence and CYP51A mutations of clinical and environmental ARAF in different geographic areas of Germany and found a higher prevalence of TR 34 /L98H and TR 46 /Y121F/T289A isolates in the environment than in clinical isolates (4%-15% vs 0%-3%), whereas some other mutations, such as G54W or M220L, were only present in clinical isolates. 20 Furthermore, except a study in which TR 46 /Y121F/ T289A isolates were found in the home of patient with IA, 19 and another one assessing eight domiciles in the Netherlands, 21 most environmental ARAF were isolated from soil or outdoor/indoor air samples in hospitals. [22] [23] [24] [25] In this study, we aimed to determine the prevalence of ARAF in azole-naïve COPD patients and their homes, and assess whether CYP51A mutations of ARAF isolates were similar in clinical and environmental reservoirs, in order to evaluate if the domestic mold environmental exposure could be a risk factor for the acquisition of ARAF isolates in these patients.
| METHODS

| Patients recruiting and clinical and environmental sampling
Forty-one patients with acute exacerbation of COPD, who had not received antifungal systemic treatment within the 6 previous months, were prospectively included in Lille University Hospital (France) from 
| Antifungal susceptibility testing
ITZ, voriconazole (VOR), posaconazole (POS), and isavuconazole (ISA)
MICs were determined for CYP51A-mutated isolates and for isolates with positive growth on ITZ medium, using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) microbroth dilution (E.Def 9.3.1) reference method for susceptibility testing. 28 EUCAST criteria were used to define susceptibility and resistance. was used as the 3D template, as A. fumigatus CYP51A shares higher sequence identity with this protein (63.6%) than with CYP51A from other organisms with available crystal structures. For that purpose, the 3D template was first modified by docking ITZ instead of VOR, applying a 3D-structural alignment with the crystal structure of yeast CYP51 bound to ITZ (PDB id 4ZDY), and then 20 models were generated using MODELLER-9v17 program. 31 Among the models, the one with the lowest energy was selected as the final model.
| RESULTS
| Characteristics of patients with COPD; prevalence of A. fumigatus colonization and domestic exposure
The mean age of patients was 63.8 ± 9.7 years old, and M/F sex ratio was 
| Phenotypic and genotypic confirmations of A. fumigatus identification
Thermotolerance at 50°C, ITS-rDNA and beta-tubulin sequencing confirmed A. fumigatus identification for all isolates. ITS-rDNA mutations were detected in 12 clinical strains from 2 patients and 13 environmental strains from 6 patient's homes, whereas only 2 environmental strains presented beta-tubulin gene mutations, one synonymous and one nonsynonymous, all other sequences having 100% identity (Table 1 ).
| Cyp51A mutations in clinical and environmental isolates
Cyp51A sequencing yielded 5 mutation profiles in 5 clinical and 5 environmental isolates from 6 different patients ( Pan-azole-resistant isolates are highlighted in gray. Synonymous mutations are in italics. OPW, oropharyngeal wash; EDC, electrostatic dust collector. *Isolates obtained after direct culture on ITZ medium of respiratory samples if more than 10 A. fumigatus colonies had been detected on media without ITZ. 
| Selection on ITZ medium and MIC determination
| Circulation of isolates within and between clinical and environmental reservoirs
Coexistence of F46Y-M172V-N248T-D255E-E427K or A284T
and WT azole-sensitive isolates in the same sample was found in sputa from patients no. 24 and 41, respectively ( 
| Geographical distribution of clinical and environmental isolates
Clinical and environmental isolates came from patients living in different parts of Northern France, but most were close to Lille (Figure 1 ).
The two TR 34 /L98H environmental isolates were found in two different cities: Faches-Thumesnil and Marcq-en-Baroeul, which are located in urban areas a few kilometers at the South and North of Lille, respectively. The H285Y isolate was also detected in FachesThumesnil, whereas the patient who was colonized with three A284T
clinical isolates was living in Marquillies, in a rural area. Isolates with F46Y-M172V-N248T-D255E-E427K and F46Y-M172V-E427K were localized in Lille and Faches-Thumesnil.
| Modeling of A. fumigatus CYP51A: structural localization of H285
In the 3D model of CYP51A, the H285 residue was a buried residue located at the N-terminal extremity of the α-helix I, which is an important part of channel 1, the main putative access to the active site ( Figure 2 ). H285 was then situated quite far from the heme moiety, but along to the entrance of the putative ligand access channel 1.
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ITZ molecule was, conversely, found in the putative channel 2.
| DISCUSSION
The 23% prevalence of A. fumigatus colonization we found during COPD acute exacerbation is similar to the 16.6%-28% ones that have been reported previously in Spain or in the UK. L98H isolates were located in urban areas. Altogether, these data confirm the presence of ARAF in the homes of patients at risk for IA that was recently reported, 19 and further indicate that exposure to environmental ARAF isolates is not limited to rural areas where fungicides F I G U R E 2 Ribbon illustrations of the Aspergillus fumigatus CYP51A 3D model. Helices/loop and strands are shown in corral and cyan, respectively. The helix I containing the H285 residue is colored in orange. The structure is showed in two different views related by a 90° rotation. The protein surface is displayed in transparency. The heme cofactor (yellow carbons), ITZ (green carbons), and residue H285 (magenta carbons) are depicted as sticks and labeled in the right view, as well as the N-and C-terminal regions. The two putative ligand access channels 32 are labeled and indicated by arrow. Oxygen, nitrogen, and iron are colored in red, blue, and orange, respectively. The images were produced using the PyMOL Molecular Graphics System (Version 1.7, Schrödinger, LLC) determination from all colonies or screening using azole-supplemented medium should be performed when patients are to be treated. 41 The usefulness of this method was confirmed in our study where two ITZresistant isolates were obtained after direct culture on ITZ medium of one EDC and one sputum, which contained more than 10 colonies.
Other CYP51A mutations included A284T, which was reported to be associated with decreased sensitivity to ITZ, VOR, and POS. 43 However, only POS and ISA MICs were discreetly increased in our study. We also identified 4 isolates harboring mutations F46Y-M172V-N248T-D255E-E427K in different combinations, giving slightly increased POS and ISA MICs. Similar combinations, mainly associated with azole sensitivity, have been previously described in Europe, 32, 44 but isolates with increased azole MICs have also been reported in Europe 6 and in the USA. 45 Interestingly, a new mutation H285Y was also identified in one environmental isolate and was associated with pan-azole resistance, ISA MIC being correlated with VOR MIC, as previously described for ARAF isolates with other CYP51A mutations. 46 Modeling the CYP51A indicated that the buried residue in position 285 was situated at the entrance of the ligand access channel 1. Although the mutation of a buried residue generally induces largest structural rearrangements, no large structural alteration of the channel 1 was found to be caused by the H285Y mutation. Furthermore, as ITZ was proposed to enter via another channel, the impact of H285Y modification on the ITZ susceptibility appears difficult to predict. Further investigations are required to precise the functional effect of this mutation, which, interestingly, is localized near the A284T and T289A mutations. [9] [10] [11] [12] [13] and is close to the 10% resistance frequency that was suggested as a threshold above which the standard treatment choice of IA with voriconazole should be reconsidered, 51 highlights the need for a surveillance of resistance rates according to Aspergillus disease and risk groups in our region.
In conclusion, the presence of ARAF in indoor environments of pa- 
